This week on “The Top Line,” we explore the European biotech investment landscape. 
Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. 
To learn more about the topics in this episode: 

'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023
'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair

 See omnystudio.com/listener for privacy information.